Dr. Roeker on the Emerging Role of MRD in CLL

Video

In Partnership With:

Lindsey Roeker, MD, discusses the emerging role of minimal residual disease as a predictive end point in chronic lymphocytic leukemia.

Lindsey Roeker, MD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the emerging role of minimal residual disease (MRD) as a predictive end point in chronic lymphocytic leukemia (CLL).

Understanding how to optimize MRD is developing in CLL, Roeker says. Clinical trials evaluating combined-modality regimens are including MRD as a predictive end point for response, Roeker explains.

A correlation between MRD negativity and prolonged progression-free survival (PFS) has been observed in patients with CLL treated with chemoimmunotherapy, Roeker says. Additionally, findings from the phase 3 MURANO trial (NCT02005471) demonstrated that undetectable MRD (uMRD) was associated with improved PFS, as well as overall survival, in patients with relapsed/refractory CLL, Roeker adds.

Additional research with ongoing trials is needed to determine whether uMRD can predict for long-term PFS benefit or whether fixed-duration treatment is a sufficient and simpler way to treat patients with CLL, Roeker concludes.

Related Videos
Anand Narayan, MD, PhD
J. Randolph (Randy) Hecht, MD
Qian (Janie) Qin, MD
Mary “Nora” Disis, MD
J. Randolph (Randy) Hecht, MD
Qian (Janie) Qin, MD
Ajai Chari, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Joachim G. J. V. Aerts, MD, PhD
Related Content